Table 3.

Randomized trials comparing anti-EGFR and anti-VEGF antibody treatment in mCRC [40 – 43, 54, 55]

	Treatment	Gene status	PFS, months	OS, months	ORR, %
FIRE-3 (n= 178) [54]	FOLFIRI + cetuximab	KRAS mutant	7.5 vs. 10.1	20.3 vs. 20.6	38 vs. 51
	vs.		p = 0.085	HR = 1.09	p = 0.097
	FOLFIRI + bevacizumab			p = 0.60
FIRE-3 (n= 592) [40]	FOLFIRI + cetuximab	KRAS wild-type	10.0 vs. 10.3	28.7 vs. 25.0	62 vs. 58
	vs.		p = 0.55	HR = 0.77	p = 0.183
	FOLFIRI + bevacizumab			p = 0.017
FIRE-3 (n = 400) [42]	FOLFIRI + cetuximab	all RAS wild-type	10.3 vs. 10.2	33.1 vs. 25.0	66 vs. 58
	vs.		p = 0.77	HR = 0.697	p = 0.92
	FOLFIRI + bevacizumab			p = 0.0059
CALGB (n = 1,137) [41]	FOLFOX/FOLFIRI + cetuximab	KRAS wild-type	10.4 vs. 10.8	29.9 vs. 29.0	66 vs. 57
	vs.	codons 12/13	HR = 1.04	HR = 0.925	p = 0.02
	FOLFOX/FOLFIRI + bevacizumab		p = 0.55	p = 0.34
CALGB (n = 526) [43]	FOLFOX/FOLFIRI + cetuximab	all RAS wild-type	11.4 vs. 11.3	32.0 vs. 31.2	69 vs. 54
	vs.		HR = 1.1	HR = 0.9	p < 0.01
	FOLFOX/FOLFIRI + bevacizumab		p = 0.31	p = 0.40
PEAK [55]	FOLFOX + panitumumab	KRAS wild-type	10.9 vs. 10.1	34.2 vs. 24.3	58 vs. 54
	vs.	exon 2	HR = 0.87	HR = 0.62	p = n.s.
	FOLFOX + bevacizumab		p = 0.353	p = 0.009
		all RAS wild-type	HR = 0.65	41.3 vs. 28.9
			p = 0.029	HR = 0.63
				p = 0.058

n.s. = Not significant.